Simvastatin in Patients With Septic Shock
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00450840 |
Recruitment Status
: Unknown
Verified September 2007 by Medical University of Vienna.
Recruitment status was: Recruiting
First Posted
: March 22, 2007
Last Update Posted
: September 17, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Septic Shock | Drug: Simvastatin | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |

- Time to shock reversal as defined by cessation of vasopressor support > 1 hour

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 18 years
- Septic Shock for less than 48 hours
Exclusion Criteria:
- Pregnancy
- Unable to receive enteral medications
- Expected survival of less than 72 hours
- Treatment in the previous 3 weeks with simvastatin or other HMG-CoA reductase inhibitors
- History of hypersensitivity to the trial drug or to drugs with a similar chemical structure
- History of known or suspected porphyria
- High risk of rhabdomyolysis (multiple trauma, crush injuries, extensive burns, baseline creatinine kinase (CK) ≥ten-times upper limit of normal
- Hemorrhagic shock

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00450840
Contact: Peter Schenk, MD | 0043-1-40400 ext 4767 | peter.schenk@meduniwien.ac.at |
Austria | |
Medical University of Vienna, Dep. of Internal Medicine III | Recruiting |
Vienna, Austria, 1090 | |
Contact: Valentin Fuhrmann, MD 0043-1-40400 ext 4767 valentin.fuhrmann@meduniwien.ac.at | |
Sub-Investigator: Valentin Fuhrmann, MD |
Principal Investigator: | Peter Schenk, MD | Medical University of Vienna, Intensive Care Unit |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00450840 History of Changes |
Other Study ID Numbers: |
3732006 |
First Posted: | March 22, 2007 Key Record Dates |
Last Update Posted: | September 17, 2007 |
Last Verified: | September 2007 |
Keywords provided by Medical University of Vienna:
septic shock simvastatin |
Additional relevant MeSH terms:
Shock Shock, Septic Pathologic Processes Sepsis Infection Systemic Inflammatory Response Syndrome Inflammation Simvastatin |
Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |